Risk stratification is the best strategy for deciding who needs medication for primary prevention of cardiovascular events
An absolute risk approach to managing cardiovascular disease (CVD) risk factors is superior to managing individual risk factors, and has been endorsed by peak professional bodies and in CVD management guidelines.1 However, clinicians need to be confident about the robustness of the risk estimates if they are to act upon them. Ideally, a CVD risk score model for patients in Australia should be based upon a large Australian cohort study including information on all relevant risk factors and a sufficient number of CVD outcomes.2 As this is not available, one applies an algorithm based on other data, such as those of the American Framingham Heart Study; the Australian Risk Calculator (https://www.cvdcheck.org.au), a recalibration of a Framingham algorithm, is currently the recommended tool. In the study published in this issue of the MJA, Albarqouni and colleagues3 compared four algorithms derived wholly or partially from Framingham data, including the 2013 Pooled Cohort Risk Equation (PCE‐ASCVD), an algorithm based on data for four American cohorts, including the Framingham study. The authors did not include the 1976 Framingham‐based algorithm in their assessment.4 The New Zealand prediction equations5 could also have been assessed as a contemporary algorithm.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012. https://www.heartfoundation.org.au/images/uploads/publications/Absolute-CVD-Risk-Full-Guidelines.pdf (viewed Jan 2019).
- 2. Backholer K, Hirakawa Y, Tonkin A, et al. Development of an Australian cardiovascular disease mortality risk score using multiple imputation and recalibration from national statistics. BMC Cardiovasc Disord 2017; 17: 17.
- 3. Albarqouni L, Doust JA, Magliano D, et al. External validation and comparison of four cardiovascular risk prediction models with data from the Australian Diabetes, Obesity and Lifestyle study. Med J Aust 2019; 210: 000–000.
- 4. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976; 38: 46–51.
- 5. Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet 2018; 391: 1897–1907.
- 6. Dunstan DW, Zimmet PZ, Welborn TA, et al. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab): methods and response rates. Diabetes Res Clin Pract 2002; 57: 119–129.
- 7. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743–753.
- 8. Ministry of Health (New Zealand). Cardiovascular disease risk assessment and management for primary care. Wellington: Ministry of Health, 2018. https://www.health.govt.nz/publication/cardiovascular-disease-risk-assessment-and-management-primary-care (viewed Jan 2019).
- 9. Ueda P, Woodward M, Lu Y, et al. Cardiovascular risk charts for 182 countries: application of laboratory‐based and office‐based risk scores to global populations. Lancet Diabetes Endocrinol 2017; 5: 196–213.
No relevant disclosures.